PMID- 30518340
OWN - NLM
STAT- MEDLINE
DCOM- 20190325
LR  - 20240426
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Dec 5
TI  - Prognostic role of myeloid-derived suppressor cells in cancers: a systematic 
      review and meta-analysis.
PG  - 1220
LID - 10.1186/s12885-018-5086-y [doi]
LID - 1220
AB  - BACKGROUND: Myeloid-derived suppressor cells (MDSCs) is a heterogeneous 
      population of immature myeloid cells, inhibiting both the innate and adaptive 
      immunity. Recent studies validated that MDSCs caused immune suppression and 
      promoted cancer progression through various mechanisms. However, the prognostic 
      value of MDSCs in cancer remains controversial. METHODS: Here, we performed this 
      meta-analysis to evaluate the prognostic value of MDSCs in various types of 
      cancer. The electric databases, such as Pubmed, Embase and Web of Science, were 
      searched for relevant publications. Hazards ratios (HRs) with the corresponding 
      95% confidence intervals (95%CIs) were calculated to evaluate the prognostic role 
      of MDSCs in cancer. RESULTS: A total of 16 studies with 1864 patients were 
      enrolled in our meta-analysis. Elevated MDSCs frequency was shown to be 
      associated with shorter overall survival (OS) (HR = 2.46, 95%CI: 1.87-3.23), and 
      poor disease-free survival / recurrence-free survival (DFS / RFS) (HR = 3.26, 
      95%CI: 2.10-5.04) after treatment. Furthermore, similar results were also 
      observed in the stratified subgroup analysis, which included the analysis by 
      region, sample size, cancer type, NOS scores, subtype and cut-off value of MDSCs. 
      CONCLUSION: High MDSCs might be related to poor clinical outcomes of patients 
      with cancer, that is, MDSCs might be a potential prognostic biomarker in cancer.
FAU - Ai, Lisha
AU  - Ai L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Mu, Shidai
AU  - Mu S
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Wang, Yadan
AU  - Wang Y
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Wang, Huafang
AU  - Wang H
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Cai, Li
AU  - Cai L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Li, Wenzhu
AU  - Li W
AD  - Institute of Geriatrics, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Hu, Yu
AU  - Hu Y
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China. dr_huyu@126.com.
LA  - eng
GR  - 81500172/the National Natural Science Foundation of China/
GR  - 81501209/the National Natural Science Foundation of China/
GR  - 81770132/the National Natural Science Foundation of China/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20181205
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*blood
MH  - Disease-Free Survival
MH  - Humans
MH  - Myeloid-Derived Suppressor Cells/*metabolism
MH  - Neoplasms/*blood/*diagnosis/epidemiology
MH  - Prognosis
PMC - PMC6280417
OTO - NOTNLM
OT  - Meta-analysis
OT  - Myeloid derived suppressor cells
OT  - Prognosis
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR 
      PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they 
      have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2018/12/07 06:00
MHDA- 2019/03/26 06:00
PMCR- 2018/12/05
CRDT- 2018/12/07 06:00
PHST- 2018/05/14 00:00 [received]
PHST- 2018/11/12 00:00 [accepted]
PHST- 2018/12/07 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/03/26 06:00 [medline]
PHST- 2018/12/05 00:00 [pmc-release]
AID - 10.1186/s12885-018-5086-y [pii]
AID - 5086 [pii]
AID - 10.1186/s12885-018-5086-y [doi]
PST - epublish
SO  - BMC Cancer. 2018 Dec 5;18(1):1220. doi: 10.1186/s12885-018-5086-y.